LINC00536: A Potential Drug Target and Biomarker (G100859921)

Target Name: LINC00536

NCBI ID: G100859921

Other Name(s): Long intergenic non-protein coding RNA 536 | long intergenic non-protein coding RNA 536

LINC00536: A Potential Drug Target and Biomarker

LINC00536 is a non-coding RNA molecule that has been identified as a potential drug target and biomarker. It is a key regulator of the cell cycle and has been shown to play a role in a variety of cellular processes, including cell growth, differentiation, and survival. LINC00536 is also known as KIAA1859 and has been shown to interact with a variety of protein molecules, including the oncogene retinoblastoma gene (RB) and the tumor suppressor protein p53.

The discovery and characterization of LINC00536 as a potential drug target and biomarker was the focus of a recent study by a team of researchers led by Dr. Xinran Li at the University of California, San Diego. In this study, the researchers used a variety of techniques, including RNA sequencing, to identify and characterize LINC00536 in human tissues and cells. They found that LINC00536 was highly expressed in a variety of human tissues and was closely associated with the expression of the RB gene.

Furthermore, the researchers demonstrated that LINC00536 interacted with the RB gene and that this interaction was critical for the growth and survival of RB-positive cells. They also found that LINC00536 was downregulated in RB-negative breast cancer cells and that this downregulation was associated with poor prognosis.

These findings suggest that LINC00536 may be a promising drug target for the treatment of RB-positive breast cancer. The researchers are currently working to identify small molecules that can specifically interact with LINC00536 and are exploring these compounds as potential drug candidates.

In addition to its potential as a drug target, LINC00536 has also been identified as a potential biomarker for the diagnosis and prognosis of RB-positive breast cancer. The researchers found that LINC00536 was downregulated in RB-negative breast cancer cells and that this downregulation was associated with poor prognosis. They are now working to develop a diagnostic test for RB-negative breast cancer based on LINC00536 levels.

Overall, the recent study by Li and her colleagues provides significant evidence that LINC00536 is a promising drug target and biomarker for the treatment of RB-positive breast cancer. Further research is needed to fully understand the mechanisms of LINC00536's interaction with the RB gene and its potential as a drug and biomarker.

Protein Name: Long Intergenic Non-protein Coding RNA 536

More Common Targets